etidronate
Small moleculeexperimental
Etidronic acid, also known as etidronate, is a bisphosphonate drug. It is non-nitrogenous bisphosphonate. It was patented in 1966 and approved for medical use in 1977. For medicinal purposes, etidronic acid has been obsolete since the early 2010's. — Wikipedia
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Sep 30, 2019 (NCT04035330)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEtidronic acid ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07210515 | Phase 3 | Mar 31, 2026 | Ambros Therapeutics, Inc. |
| NCT05832580 | Phase 3 | Apr 26, 2023 | Utrecht University |
| NCT05662111 | Phase 2 | Feb 28, 2023 | Netherlands Brain Foundation, Utrecht University |
| NCT05781633 | N/A | Jul 20, 2022 | Tianjin Medical University |
| NCT04035330 | N/A | Sep 30, 2019 | Cairo University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Utrecht University | Academic/Hospital | 2 | 2 | 2 | 2023 |
| Ambros Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2026 |
| Cairo University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Netherlands Brain Foundation | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Tianjin Medical University | Academic/Hospital | 1 | 1 | 1 | 2022 |
5 organizations
Page 1 / 1